DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

Information source: Hospital Geral de Fortaleza
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Transplantation Infection; Cytomegalovirus Infections

Intervention: Everolimus (Drug); Very Low Tacrolimus (Drug); Low Tacrolimus (Drug); Steroids (Drug); Thymoglobulin (Drug); Sodium Mycophenolate (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Ronaldo de Matos Esmeraldo, MD

Official(s) and/or principal investigator(s):
Ronaldo M Esmeraldo, MD, Principal Investigator, Affiliation: Hospital Geral de Fortaleza


This is a 12-month single center, randomized, open-label, single center study designed to compare the safety and efficacy of everolimus and very low dose tacrolimus versus enteric-coated sodium mycophenolate and low tacrolimus exposure in de novo kidney transplant recipients. The purpose of this study is to compare safety and efficacy of two immunosuppressive regimens based on low tacrolimus exposure combined to everolimus or to enteric-coated mycophenolate sodium (EC-MPS) in de novo kidney transplant recipients.

Clinical Details

Official title: Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: Incidence of cytomegalovirus (CMV) infection (viremia) or disease (syndrome or invasive disease) during the first year of transplantation

Secondary outcome:

Composite efficacy failure rates demonstrated by treated biopsy proven acute rejection episodes (BPAR), graft loss, death, loss to follow-up at months 6 and 12

• Graft function measured as calculated creatinine clearance according to the Cockcroft and Gault formula at 6 and 12 months after transplantation

Incidence of proteinuria

Safety Secondary Objectives - incidence of bone marrow suppression, gastrointestinal events, BKV infection, new onset diabetes mellitus; malignancies, dyslipidemia.

Incidence of cytomegalovirus (CMV) infection (viremia) or disease (syndrome or invasive disease) during the first year of transplantation

Detailed description: The study will consist of two periods: an initial period of 3 months during which all patients in both groups will be monitored in accordance with the same variation of C-0h tacrolimus and a second study period of 9 months (from month 4 to month 12) in which patients will be monitored according to two different targets of C-0h tacrolimus. At the screening visit and before any assessment related to the study, patients must give their informed consent in writing. All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1. 5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice. The evaluations of baseline visit occur within 24 hours after transplantation and prior to the first dose of study drug. Randomization will be performed within 24 hours after transplantation and after the baseline visit assessments. Patients will be randomized in a 1: 1 ratio to one of two groups (everolimus with very low dose of tacrolimus versus sodium mycophenolate with low dose of tacrolimus). Approximately 120 patients who meet the inclusion criteria will receive their first dose everolimus (initial dose of 1 mg twice a day) or sodium mycophenolate (initial dose of 720 mg twice a day) not more than 24 hours after transplantation. Everolimus trough blood levels will be measured at pre-specified timepoints in order to ensure that trough levels are above 3 ng/ml and below 8 ng/ml for the duration of the study. Tacrolimus will be started within 48 hours after graft reperfusion at an initial dose of 0. 1 mg/kg/day. The dose of tacrolimus will be adjusted to target the C-0h value within the pre-established desired range. In the everolimus group with very low dose of tacrolimus, tacrolimus dose should be reduced at the end of months three after transplantation. Patients with either acute rejection grade ≥ Banff IIB or more than one treated acute rejection since entering the study and patients with either acute rejection during the third month will not have the dose of tacrolimus reduced; however, they will be encouraged to remain in the study. These patients will be excluded from the per protocol population analysis, but will be analyzed in the Intention To Treat population. If patients present delayed graft function (DGF), the start of tacrolimus can be postponed for up to and including 7 days. During the 12 months treatment period, patient visits will occur at the selection visit, baseline visit, at 1, 2, 4 and 8 weeks and at 3, 6 and 12 months. Day 1 is the day of the first administration of everolimus or sodium mycophenolate. Population: Study population will consist of a group of male or female transplant recipients 18-75 years of age undergoing primary renal transplantation and who received an organ from a living or deceased donor.


Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.


Inclusion Criteria:

- Male or female renal recipients 18-75 years of age undergoing kidney transplantation,

from a primary deceased donor (including expanded criteria donor organs), living unrelated or non-HLA identical living related donor kidney;

- Recipient of a kidney with a cold ischemia time < 30 hours;

- Graft must be functional (producing greater than or equal to 300 ml of urine within

24 hours after transplantation) at time of randomization. Exclusion Criteria:

- Donor organ with a cold ischemic time > 30 hours;

- Patients who produce less than 300 ml of urine in the first 24 hours


- Patients who are recipients of multiple organ transplants;

- Patients who are recipients of ABO incompatible transplants, or T or B cell cross

match positive transplant;

- Patients with current Panel Reactive Antibodies (PRA) level ≥ 50%;

- Patients with severe hypercholesterolemia (350 mg/dl) or hypertriglyceridemia (500

mg/dl). Patients on lipid lowering treatment with controlled hyperlipidemia are acceptable;

- HIV positive patients;

- Females of childbearing potential who are planning to become pregnant, who are

pregnant and/or lactating, who are unwilling to use effective means of contraception;

- Decisional impaired subjects who are not medically or mentally capable of providing

consent themselves.

Locations and Contacts

Hospital Geral de Fortaleza, Fortaleza, Ceará 60175-295, Brazil
Additional Information

Starting date: December 2012
Last updated: March 18, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017